BioArctic AB Class B

As of June 30, 2026, BioArctic AB Class B carries a market capitalization of 29.06B, placing it among publicly traded companies globally. Its enterprise value stands at 27.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioArctic AB Class B's next confirmed earnings release is scheduled for November 25, 2026.

As of June 30, 2026, BioArctic AB Class B has 88.72M shares outstanding.

As of June 30, 2026, BioArctic AB Class B trades at a trailing price-to-earnings ratio of 275.12. The price-to-sales ratio is 28.96, and the price-to-book ratio stands at 14.41.

As of June 30, 2026, BioArctic AB Class B trades at an EV/EBITDA multiple of 130.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 27.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 130.05 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BioArctic AB Class B trades at an EV/FCF ratio of 109.58, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 27.16B versus a market cap of 29.06B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioArctic AB Class B maintains a current ratio of 3.99, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.49, indicating elevated leverage, while an interest coverage ratio of 22.93 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioArctic AB Class B posted a return on equity (ROE) of 5.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.23 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.10, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.22, useful for judging operating efficiency across full business cycles. The company generates approximately 8.02M in revenue per employee across its workforce of 125.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BioArctic AB Class B recorded 143.11M in income tax expense. That works out to an effective tax rate of 57.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 248.63M, leaving 105.52M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BioArctic AB Class B's stock has gained approximately 0.98% over the past 52 weeks. The 50-day moving average sits at 316.84, while the 200-day moving average is 317.32.

Over the twelve months ended June 30, 2026, BioArctic AB Class B generated 1.00B in revenue and converted that into 105.52M in net income, yielding earnings per share of 1.19. EBITDA reached 208.82M, while operating income came in at 208.82M.

As of June 30, 2026, BioArctic AB Class B holds 1.99B in cash and equivalents against 90.61M in total debt, resulting in a net debt position of -1.08B. Total book value stands at 2.02B, with working capital of 2.01B providing operational flexibility.

BioArctic AB Class B produced 243.98M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BioArctic AB Class B posted a gross margin of 93.17, reflecting its pricing power and cost economics. The operating margin of 20.83 and net profit margin of 10.53 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.84, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioArctic AB Class B shareholders.